Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for
participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be
locoregionally administered via a CNS reservoir catheter. Study participants will be divided
into two cohorts: cohort A with B7-H3-positive relapsed/refractory non-brainstem primary CNS
tumors, and cohort B with brainstem high-grade neoplasms. Participants will receive six (6)
B7-H3-CAR T cell infusions over an 8 week period. The purpose of this study is to find the
maximum (highest) dose of B7-H3-CAR T cells that are safe to give patients with primary brain
tumors.